Treatment of Small Cell Lung Cancer, Limited Stage (IIB–IIIC) in Patients with Good Performance Status
This protocol addresses the first-line management of small cell lung cancer (SCLC) in the limited stage, specifically clinical stage IIB–IIIC disease (T3–4,N0,M0 or T1–4,N1–3,M0) in patients with an ECOG performance status of 0–2.
Clinical Scenario
- Histology: Small cell lung cancer (SCLC)
- Disease extent: Limited stage — clinical stage IIB–IIIC (T3–4,N0,M0; T1–4,N1–3,M0)
- Functional status: ECOG performance status 0–2 (good)
Treatment Approach
The recommended first-line approach combines systemic chemotherapy with concurrent thoracic radiation therapy — a category 1 recommendation for this population. A platinum-based chemotherapy regimen is used alongside the radiation phase. For patients who do not have disease progression after completing concurrent chemoradiation, a consolidation immunotherapy regimen may then be continued. The specific agents, selection criteria, and full treatment algorithm are detailed in the structured protocol.
Treatment Goal
Complete or partial response on imaging after completion of initial therapy. Response assessment is performed following the conclusion of initial treatment.
References
- Good performance status (PS) (0–2)
- Limited stage IIB–IIIC (T3–4,N0,M0; T1–4,N1–3,M0)
- Systemic therapy + concurrent RT (category 1)
- During cytotoxic chemotherapy + RT, Cisplatin/Etoposide is recommended (category 1).
- Those who did not experience disease progression after systemic therapy + concurrent RT may continue durvalumab until disease progression or intolerable toxicity, or for a maximum of 24 months.
- For patients receiving systemic therapy + concurrent RT, response assessment is recommended only after completion of initial therapy (SCL-6).
View source ↗